PTC Therapeutics Inc. (PTCT)
NASDAQ: PTCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 63.23 0.00%
PTCT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.28B
- Forward P/E
- 23.62
- EPS (TTM)
- -$0.65
- Dividend yield
- None
- 52-week range
- 61.23 – 90.87
- Day range
- 62.84 – 64.04
- Volume / Avg
- 1.04M / 1.15M
- Beta
- —
- Shares outstanding
- 83.46M
- Next earnings
- Nov 3, 2026
52-week range
PTCT stock today
On Oct 7, PTCT ended the session at $63.23, shedding $0.47 (0.74%), versus the S&P 500's 0.22% decline. Shares are 30.4% below their 52-week high of $90.87, set on Jul 9, 2026 and 3.3% above the 52-week low of $61.23, near the bottom of the past year's range. PTCT is down 16.8% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 1.1%.
PTC Therapeutics has posted a net loss over the last twelve months (EPS of -$0.65), so its P/E ratio is not meaningful. PTC Therapeutics's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About PTC Therapeutics
Company profilePTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
- Headquarters
- Warren, NJ
- Employees
- 991
- IPO year
- 2013
- Website
- ptcbio.com
Financial highlights
Full financialsIn fiscal 2025, PTC Therapeutics generated $1.73 billion in revenue, up 114.5% from fiscal 2024. Net income was $682.6 million, for a net margin of 39.4% versus a median of -80.0% in the prior 5 years. Operating margin was 50.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.73B | $806.78M | $937.82M | $698.80M | $538.59M |
| Growth | +114.51% | -13.97% | +34.20% | +29.75% | +41.45% |
| Net income | $682.64M | $-363.30M | $-626.60M | $-559.02M | $-523.90M |
| EPS (diluted) | $7.78 | $-4.73 | $-8.37 | $-7.79 | $-7.43 |
Analyst forecast
ForecastConsensus (14 analysts)
buy
Avg. price target
$101.79+60.98%
- Strong buy 4
- Buy 8
- Hold 1
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $0.15
- Last reported (Q2 2026)
- Jul 30, 2026
- EPS actual vs est.
- $0.92 vs —
PTC Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| MIRMMirum Pharmaceuticals Inc. | 80.64 | +1.75% | $5.24B | vs PTCT |
| COGTCogent Biosciences Inc. | 30.14 | -0.79% | $5.23B | vs PTCT |
| GRFSGrifols S.A. ADR | 7.50 | -0.27% | $5.10B | vs PTCT |
| TVTXTravere Therapeutics Inc. | 53.44 | -4.54% | $5.04B | vs PTCT |
| ERASErasca Inc. | 14.12 | -1.26% | $4.94B | vs PTCT |
| LGNDLigand Pharmaceuticals Incorporated | 293.26 | -1.24% | $5.85B | vs PTCT |
| DNTHDianthus Therapeutics Inc. | 84.88 | -0.61% | $4.75B | vs PTCT |
| MANEVeradermics Incorporated | 110.95 | +1.83% | $4.64B | vs PTCT |
Indexes, lists and sector
PTC Therapeutics stock FAQ
What is PTC Therapeutics's stock price today?
PTCT last traded at $63.23 as of Oct 7, 4:00 PM EDT, down 0.74% on the day. Prices are delayed at least 15 minutes.
When is PTC Therapeutics's next earnings date?
PTC Therapeutics is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $0.15.
Who is PTC Therapeutics's CEO?
Dr. Matthew B. Klein F.A.C.S., M.D., M.S. is the chief executive officer of PTC Therapeutics Inc., which has about 991 employees.
What is the PTCT 52-week high?
The 52-week high for PTCT is $90.87 and the 52-week low is $61.23. The stock is currently 30.4% below its high.